List of Excipients in Branded Drug ZIDOVUDINE

Generic Drugs Containing ZIDOVUDINE

Company	Ingredient	NDC	Excipient
Lannett Company Inc	zidovudine	0527-1905	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	zidovudine	0527-1905	HYPROMELLOSES
Lannett Company Inc	zidovudine	0527-1905	LECITHIN, SOYBEAN
Lannett Company Inc	zidovudine	0527-1905	MAGNESIUM STEARATE
Lannett Company Inc	zidovudine	0527-1905	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in ZIDOVUDINE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
13	CELLULOSE, MICROCRYSTALLINE
1	CITRIC ACID MONOHYDRATE
1	FD&C BLUE NO. 1
3	FERROSOFERRIC OXIDE

Zidovudine Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Zidovudine is an off-patent nucleoside reverse transcriptase inhibitor with established oral, liquid, intravenous, and fixed-dose combination use. The strongest commercial opportunities are in pediatric taste-masked liquids, low-cost dispersible or multiparticulate dosage forms, stable fixed-dose combinations, and excipient systems that improve manufacturability in tropical and resource-limited markets. Core active-ingredient exclusivity is no longer the main barrier; formulation performance, regulatory compliance, supply reliability, and cost determine competitiveness.

What excipients are used in zidovudine products?

Approved zidovudine products use conventional excipients selected for immediate release, content uniformity, taste acceptability, and chemical stability.

Dosage form	Representative excipient functions	Commercial relevance
Immediate-release tablets	Lactose, microcrystalline cellulose, starch-based disintegrants, magnesium stearate, colloidal silicon dioxide, film-coating agents	Lowest-cost adult presentation
Capsules	Lactose or other diluent, starch, lubricants, gelatin shell, colorants	Established but less flexible for pediatric use
Oral solution, commonly 10 mg/mL	Purified water, sucrose or other sweetener, glycerin or polyol, buffers, preservatives, flavors	Pediatric and swallowing-limited patients
Intravenous solution	Water for injection, sodium chloride or other tonicity agents, pH adjusters	Hospital and perinatal use
Fixed-dose combinations	Tablet diluents, binders, disintegrants, lubricants, coating systems	Simplified HIV treatment and lower pill burden

The U.S. Retrovir label identifies conventional tablet and capsule excipients, including lactose, microcrystalline cellulose, starch-derived disintegrants, magnesium stearate, titanium dioxide, gelatin, and colorants. The oral solution uses a sweetened, flavored aqueous system with buffering and preservative components. Product-specific compositions vary by manufacturer and market, so formulation equivalence cannot be assumed from the innovator label alone (U.S. Food and Drug Administration [FDA], 2019).

Which excipient functions matter most for zidovudine?

Solubility and dissolution control

Zidovudine has sufficient aqueous solubility for conventional immediate-release products, which reduces the commercial need for complex lipid or amorphous solid-dispersion systems. Excipient selection should therefore prioritize:

• Rapid and reproducible disintegration
• Low variability in dissolution
• Adequate powder flow
• Robust tablet compression
• Compatibility with high-volume generic manufacturing

Microcrystalline cellulose, lactose, starch, crospovidone, croscarmellose sodium, and sodium starch glycolate are practical choices. A formulation that relies on a high level of hydrophobic lubricant may show slower dissolution, particularly after scale-up. Lubrication time and magnesium stearate concentration require process controls.

Taste masking

Taste is the central formulation issue for pediatric zidovudine. The active ingredient has an unpleasant taste that can reduce adherence when administered as an aqueous liquid. Commercially relevant approaches include:

1. Sweetener and flavor systems using sucrose, sorbitol, glycerin, sucralose, or similar agents.
2. Ion-exchange resin complexes that reduce free drug exposure in the mouth.
3. Polymer coating of drug particles.
4. Lipid or wax-based taste-masking systems.
5. Multiparticulate granules administered with soft food or water.
6. Orally disintegrating or dispersible tablets with rapid mouth clearance.

Simple sweetening is inexpensive but may not sufficiently suppress bitterness. Resin complexation and coated particles can improve palatability but add manufacturing steps, analytical requirements, and potential dissolution risk. The best commercial design depends on target age, dose volume, local excipient availability, and the regulatory pathway.

Chemical and microbiological stability

Aqueous zidovudine products require control of pH, preservative performance, container compatibility, and microbial quality. Important development variables include:

• Buffer capacity and target pH
• Preservative concentration and preservative effectiveness
• Headspace oxygen and light exposure
• Sorption to plastic containers
• Extractables and leachables
• In-use stability after opening
• Stability under temperature excursions

For markets with inconsistent cold-chain access, a concentrated powder for reconstitution may have a stronger commercial profile than a ready-to-use liquid. The powder can reduce shipping weight and improve shelf stability, although it shifts risk to reconstitution accuracy, local water quality, and caregiver instructions.

What formulation opportunities exist for zidovudine?

Pediatric oral liquids

Pediatric liquid products remain the most defensible formulation opportunity because treatment must accommodate infants and children who cannot swallow tablets. A differentiated product could combine:

• Lower administration volume
• Improved taste masking
• Preservative-free unit-dose packaging
• Dosing syringes with low dead volume
• Clear reconstitution instructions
• Stability after opening
• Compatibility with nasogastric administration

A 10 mg/mL liquid requires a 10 mL dose for a 100 mg administration. Higher-strength products could reduce volume, but they raise dose-measurement and palatability concerns. The commercial opportunity is strongest where pediatric HIV programs require dependable supply and where caregivers administer multiple daily doses.

Dispersible and multiparticulate tablets

Dispersible tablets can reduce logistics costs and support pediatric dosing without requiring a liquid manufacturing line. A scored or dispersible product can also enable dose flexibility. Key design challenges are rapid dispersion, acceptable mouthfeel, low friability, and preservation of dose uniformity after splitting.

Multiparticulates can offer better dose flexibility than fixed-strength tablets. A coated-particle system may also integrate taste masking with controlled dispersion. The tradeoff is higher process complexity and a greater need for particle-size, coating-thickness, and dissolution controls.

Fixed-dose combinations

Zidovudine has been used in combination products with lamivudine and other antiretrovirals. Combivir, containing zidovudine and lamivudine, is an established example of a fixed-dose tablet. Trizivir contains zidovudine, lamivudine, and abacavir (FDA, 2023).

Fixed-dose combinations create excipient and manufacturing challenges:

• Different active ingredients may have incompatible compression behavior.
• Dose ratios can produce large tablets.
• One active may be sensitive to moisture or oxidation.
• Dissolution specifications must be met for each drug.
• Lubricant and binder selection must avoid disadvantaging the lower-dose component.
• Coating systems must support stability without increasing tablet size excessively.

The commercial opportunity is strongest in markets where zidovudine remains part of prevention of mother-to-child transmission, salvage therapy, or public-sector treatment protocols. Its role in first-line adult HIV treatment has declined as tenofovir- and integrase-inhibitor-based regimens have become more prominent (World Health Organization [WHO], 2021).

Hospital and perinatal presentations

Intravenous zidovudine remains relevant in selected hospital and perinatal settings. Commercial differentiation is less likely to come from novel excipients than from:

• Ready-to-use containers
• Low-volume presentations
• Compatibility with infusion systems
• Reduced preparation steps
• Improved container closure integrity
• Preservative-free single-use packaging

Hospital buyers value operational simplicity and error reduction. A ready-to-administer product can command a supply or procurement advantage even when the active ingredient is commoditized.

How should manufacturers select excipients for zidovudine?

A practical excipient strategy should start with the target market and dosage form rather than with novelty.

Development objective	Preferred excipient approach	Main risk
Lowest unit cost	Lactose, microcrystalline cellulose, starch, standard lubricant	Variable flow or dissolution after scale-up
Pediatric taste masking	Resin complex, coated particles, intense sweetener and flavor system	Delayed release or poor palatability
Tropical stability	Low-moisture excipients, protective packaging, robust preservative system	Hygroscopicity and microbial growth
Pediatric dose flexibility	Dispersible tablet, scored tablet, multiparticulate granules	Dose nonuniformity after subdivision
Preservative-free liquid	Unit-dose packaging or aseptic manufacture	Higher packaging and production cost
Fixed-dose combination	Direct compression or controlled wet granulation with compatibility screening	Compression and dissolution imbalance
Global procurement	Compendial, widely available excipients	Limited differentiation

Excipient compatibility studies should assess assay, degradation products, dissolution, water activity, moisture uptake, and physical changes under accelerated conditions. Zidovudine products should also be evaluated for potential formation of degradation products under oxidative, thermal, and high-humidity stress.

What regulatory issues affect zidovudine excipient commercialization?

FDA regulatory status

Zidovudine is an FDA-approved antiretroviral. Retrovir was approved for HIV treatment, and zidovudine has also been incorporated into approved combination products. Generic development generally proceeds through an abbreviated new drug application when the dosage form, strength, route, and product characteristics qualify for the applicable pathway (FDA, 2019; FDA, 2023).

An excipient change can affect:

• Pharmaceutical equivalence
• Dissolution similarity
• Bioequivalence
• Product stability
• Labeling
• Pediatric acceptability
• Container-closure requirements
• Inactive-ingredient limits

A novel excipient or an unusual route of administration can increase regulatory burden. The commercial case for a new excipient must therefore show a clear benefit, such as materially better taste masking, reduced dose volume, improved stability, or a new pediatric presentation.

Orange Book status

The FDA Orange Book lists approved drug products and certain patent and exclusivity information. Zidovudine active-ingredient protection is historical, and current generic competition is established. Any development or litigation assessment should use the current Orange Book entry for the relevant reference-listed drug and dosage form because listings, delistings, and product status can change (FDA, 2024).

Formulation-related commercial protection may arise from a later patent or regulatory exclusivity period, but an excipient system is not automatically protected merely because it is used in an approved product. Protection depends on claim scope, priority date, prosecution history, and whether the claims cover the specific composition, process, or use.

What patents protect zidovudine formulations?

Zidovudine’s foundational compound patents expired long ago. The commercially relevant IP questions now concern later formulation, combination, manufacturing, and method-of-use rights.

Formulation patents

Potential claim categories include:

• A zidovudine liquid with defined pH and preservative concentration
• A taste-masked zidovudine particle or resin complex
• A dispersible tablet with a specified disintegration profile
• A stable fixed-dose combination
• A particular excipient ratio
• A manufacturing process that controls impurities
• A container-closure system that improves stability

A narrow excipient claim may be difficult to enforce if competitors can achieve equivalent performance with different excipients. Broad functional claims may face written-description, enablement, or obviousness challenges, particularly for a well-known immediate-release active.

Method-of-use patents

Historical zidovudine method-of-use rights covered treatment of HIV, prevention of maternal-fetal transmission, and related antiviral applications. Those rights generally have limited commercial value today because the relevant foundational protection has expired and alternative antiretroviral regimens are widely available.

Paragraph IV challenges

A generic applicant may file a Paragraph IV certification against an unexpired Orange Book-listed patent. For mature zidovudine products, the principal risk is usually not a compound patent challenge but a dispute involving:

• A later-listed formulation patent
• A combination-product patent
• A manufacturing patent
• A pediatric delivery system
• A method-of-use patent

The practical risk is lower where the generic can design around formulation claims and certify that the product label omits protected uses. Patent-risk analysis must distinguish the active ingredient from the specific reference product.

When does zidovudine lose exclusivity?

Zidovudine has already lost primary compound exclusivity in major markets. Generic and multisource products have been available for many years. Remaining commercial barriers are product-level rather than molecule-level.

Protection category	Current strategic position
Compound patent	Historical; no longer the principal barrier
Original HIV treatment use	Historical protection
Pediatric use	Commercially relevant but generally not a current compound-exclusivity barrier
Fixed-dose combinations	Product-specific protection depends on the relevant patent record
Formulation patents	Must be assessed product by product
Regulatory exclusivity	No broad current exclusivity should be assumed for the mature active
Biosimilar protection	Not applicable because zidovudine is a small molecule

Is there biosimilar risk for zidovudine?

No. Zidovudine is a chemically synthesized small molecule, not a biologic. It is subject to generic-drug competition rather than biosimilar competition. The relevant entry pathway is an ANDA or equivalent national generic pathway, not a biosimilar application under the Public Health Service Act.

This distinction matters commercially. Manufacturers do not need to reproduce a biologic reference product’s higher-order structure, but they must demonstrate pharmaceutical equivalence and, where required, bioequivalence and comparative dissolution.

Which companies compete in zidovudine?

Competition is fragmented across originator, generic, contract-manufacturing, and public-sector suppliers. The original product was developed by Burroughs Wellcome and marketed as Retrovir. GlaxoSmithKline later held the relevant commercial portfolio, while ViiV Healthcare became the principal HIV-focused company associated with GSK’s HIV business.

Generic competition has included multinational and regional manufacturers. Supplier identity varies by country, procurement framework, and product status. The most important competitive variables are:

• Lowest landed cost
• WHO or national regulatory approval
• Reliable active-ingredient supply
• Pediatric dosage-form availability
• Batch release performance
• Stability in hot and humid climates
• Ability to support public tenders
• Packaging and dosing-device quality

What licensing deals affect zidovudine?

Zidovudine has been associated with historical commercialization and combination-product arrangements involving the original innovator and later HIV-focused businesses. The principal commercial licensing value today is limited because the active ingredient is generic and treatment guidelines have shifted toward newer regimens.

Licensing opportunities remain possible for:

• Pediatric formulation technology
• Taste-masking platforms
• Regional supply rights
• Fixed-dose combination products
• Public-sector procurement
• Manufacturing technology transfer
• Ready-to-use injectable packaging

A formulation technology owner is more likely to obtain commercial value through a manufacturing or supply agreement than through broad exclusivity over zidovudine itself.

What generic launch scenarios exist for zidovudine?

Low-cost conventional tablet

This is the simplest entry strategy. It relies on established excipients, standard equipment, and a mature regulatory pathway. Price competition is intense, so margins depend on scale and procurement access.

Differentiated pediatric liquid

This strategy targets a narrower but more defensible segment. Commercial value depends on superior taste, lower dosing volume, longer in-use stability, and reliable pediatric distribution.

Dispersible or multiparticulate product

This format can address pediatric and swallowing-limited populations while reducing the logistics burden of a ready-to-use liquid. It requires more formulation development but may avoid direct competition with standard tablets.

Fixed-dose combination

A combination product can reduce pill burden and improve procurement efficiency. The main risks are tablet size, compatibility, bioequivalence, and whether the regimen remains guideline-preferred.

Hospital-ready injectable

This strategy competes on workflow and safety rather than active-ingredient novelty. It is most relevant to institutional customers and perinatal treatment settings.

How strong is the zidovudine patent estate?

The estate is weak for the active ingredient and mature indications but can be meaningful for narrow, later-developed delivery systems. Patent strength should be assessed using five factors:

1. Whether claims cover the product sold, not merely a broad concept.
2. Whether alternative excipients can avoid infringement.
3. Whether the formulation delivers a measurable clinical or pharmaceutical benefit.
4. Whether the patent has enforceable geographic coverage.
5. Whether the patent term extends beyond product development and launch timelines.

A conventional tablet with standard excipients is unlikely to have a strong new patent position. A technically difficult taste-masked pediatric system, especially one with demonstrated stability and adherence advantages, has a stronger basis for formulation protection and licensing.

What revenue exposure exists for zidovudine?

Zidovudine is unlikely to represent a material growth driver for large multinational HIV companies. Revenue exposure is more relevant to:

• Regional generic manufacturers
• Public-sector suppliers
• Pediatric HIV specialists
• Contract manufacturers
• Excipient and taste-masking technology providers
• Companies supplying antiretroviral combinations

Revenue potential is volume-driven and concentrated in tenders, government programs, and institutional purchasing. Premium pricing is difficult to sustain for standard tablets. A differentiated pediatric or hospital presentation offers better pricing potential but addresses a smaller market.

Key Takeaways

• Zidovudine is a mature, off-patent small-molecule antiretroviral.
• Standard tablets and capsules are highly commoditized.
• Pediatric taste masking is the clearest formulation opportunity.
• Dispersible tablets, multiparticulates, and concentrated or reconstituted liquids can improve commercial differentiation.
• Fixed-dose combinations remain relevant but face formulation and regimen-selection constraints.
• Biosimilar risk does not apply; generic risk is established and persistent.
• Current commercial protection depends on product-specific formulation, manufacturing, or combination patents.
• Excipient novelty alone is insufficient. The strongest opportunity combines improved palatability, stability, dose flexibility, and low manufacturing cost.
• Revenue is more likely to come from public procurement and specialized dosage forms than from premium adult tablet sales.

FAQs

Can zidovudine be formulated with modern co-processed excipients?

Yes. Co-processed microcrystalline cellulose, lactose, mannitol, and disintegrant systems can improve flow, compression, and tablet robustness. The formulation still requires comparative dissolution and stability testing.

Is a preservative-free zidovudine oral liquid commercially viable?

Yes, particularly in unit-dose packaging or aseptic presentations. The higher packaging and manufacturing cost must be balanced against improved tolerability and reduced preservative exposure.

Can zidovudine be made into an orally disintegrating tablet?

Yes. The main development barriers are taste masking, drug loading, tablet strength, friability, and rapid dispersion. An orally disintegrating tablet is more commercially credible for selected pediatric or swallowing-limited populations than as a mass-market adult product.

Which excipient platform offers the best patent opportunity?

A platform that combines taste masking with rapid release and demonstrated stability has stronger patent potential than a conventional sweetener-flavor system. Resin complexes, coated microparticles, and multiparticulate systems are more defensible when performance data support the claims.

Does zidovudine require cold-chain distribution?

Standard oral tablets generally do not require cold-chain distribution when stored according to the approved label. Liquid and injectable products require tighter control of temperature, packaging, microbial quality, and in-use stability.

References

1. U.S. Food and Drug Administration. (2019). Retrovir (zidovudine) prescribing information.
2. U.S. Food and Drug Administration. (2023). Combivir and Trizivir prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. Geneva, Switzerland: World Health Organization.